Cost-effectiveness analysis of HIV/AIDS “Test and treat” ...

Geffrey Li

• 17 maart 2015
• 9783656921646

Samenvatting:

Seminar paper from the year 2015 in the subject Medicine - Other, Johns Hopkins University, language: English, abstract: A more aggressive strategy “test and treat” is predicted to reduce AIDS-related mortality, increase the life expectancy of people living with HIV and is cost-effective. However, the cost-effectiveness studies related to “test and treat” strategy did not consider the possibility of increased drug resistance due to poor adherence, which is not rare in developing countries. There is a need for a cost-effectiveness analysis related to “test and treat” strategy in developing countries that includes drug resistance as an important parameter. This analysis is to support the government of Botswana to examine the cost-effectiveness of a HIV/AIDS “test and treat” strategy vs. current treatment guideline, which is providing treatment to patients with a CD4 count of <350 cells/ μL.